Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 6/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 6/20 | 0.43 |
| ▸ | PLK1 | P53350 | 1/20 | 0.42 |
| ▸ | NRP1 | O14786 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.39 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | GRB2 | P62993 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385468 | 0.92 | NRP1 (0.43) | NMUR2NMUR1PLK1NRP1OPRM1 | |
| SCHEMBL30658569 | 0.91 | NMUR2 (0.40) | NMUR2NMUR1PLK1NRP1OPRM1 | |
| SCHEMBL29496452 | 0.90 | PLK1 (0.44) | PLK1OPRM1OPRD1GRB2 | |
| SCHEMBL29823805 | 0.89 | RAMP3 (0.39) | PLK1NRP1GRB2 | |
| SCHEMBL30329534 | 0.88 | OPRM1 (0.41) | NMUR2NMUR1PLK1NRP1OPRM1 | |
| SCHEMBL31410831 | 0.88 | KEAP1 (0.42) | PLK1NRP1 | |
| SCHEMBL29496428 | 0.86 | RAMP3 (0.43) | PLK1 | |
| SCHEMBL30745234 | 0.86 | GRB2 (0.42) | NMUR2NMUR1PLK1OPRM1GRB2 | |
| SCHEMBL30379247 | 0.86 | PLK1 (0.41) | PLK1 | |
| SCHEMBL29823809 | 0.86 | RAMP3 (0.45) | PLK1NRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2026-02-26 | — | — | US | claimed |
| CN-119317364-A | Novel isolated peptides, protein hydrolysates comprising said isolated peptides and uses thereof | 丰年(大众)有限公司 | 2025-01-14 | — | — | CN | claimed |
| WO-2023218231-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2023-11-16 | — | — | WO | claimed |
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2026-02-26 | — | — | US | disclosed |
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2026-02-26 | — | — | US | disclosed |
| JP-2025518505-A | — | ベタグロ パブリック カンパニー リミテッド | 2025-06-17 | — | — | JP | disclosed |
| CN-119317364-A | Novel isolated peptides, protein hydrolysates comprising said isolated peptides and uses thereof | 丰年(大众)有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2023218231-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | BETAGRO PUBLIC COMPANY LIMITED (TH) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055137-A1 | NOVEL ISOLATED PEPTIDES, PROTEIN HYDROLYSATE COMPRISING THE SAID ISOLATED PEPTIDES AND USE THEREOF | VIP, ARGLU1, PELP1 | NMUR2 2846/4885NMUR1 2223/4885PLK1 3402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.